Midazolam intranasal - OptiNose
Alternative Names: Intranasal midazolam spray - OptiNoseLatest Information Update: 31 Dec 2021
At a glance
- Originator OptiNose AS
- Developer MedPharm
- Class 3-ring heterocyclic compounds; Antiepileptic drugs; Benzodiazepines; Chlorinated hydrocarbons; Fluorobenzenes; Hypnosedatives; Imidazoles; Sleep disorder therapies; Small molecules
- Mechanism of Action GABA A receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Anaesthesia
Most Recent Events
- 31 Mar 2005 Discontinued - Phase-I for Anaesthesia in Norway (Intranasal)
- 06 Feb 2005 Phase-I clinical trials in Anaesthesia in Norway (Intranasal)